All In Biotech

Drug Trial Radar · NCT04971291

An Evaluation of AXS-05 for the Treatment of TRD in Treatment-Adherent Patients

A Randomized, Active-Controlled, Evaluation of AXS-05 for the Treatment of Treatment Resistant Depression in Treatment-Adherent Patients

Last checked: Nov 19, 2026Latest source record: Jul 26, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 312 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

312

Planned (sponsor's estimate)

Start

Apr 14, 2021

Primary completion

Jul 2021

Study completion Jul 2021

Sponsor

Lead sponsor
Axsome Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The TARGET study is an active-controlled evaluation of AXS-05 compared to bupropion in patients with treatment-resistant major depressive disorder (MDD) who are adherent to study drug. Subjects are considered to have treatment-resistant MDD if they have had a historical inadequate response to 1 or 2 prior antidepressant treatments (ADTs) and a prospective inadequate response to treatment with bupropion SR, during the current major depressive episode. The TARGET study will first determine treatment adherence based on analysis of drug concentrations of dextromethorphan (in the AXS-05 group) and bupropion (in the bupropion group), and then evaluate the efficacy of AXS-05 in patients determined to be treatment-adherent. Efficacy data for evaluation of treatment effect will be obtained from assessments made during study AXS-05-301.

Conditions

  • Major Depressive Disorder
  • Treatment Resistant Depression

Interventions

  • AXS-05Drug

    AXS-05 taken twice daily for 6 weeks

  • Bupropion SRDrug

    Bupropion taken twice daily for 6 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Montgomery-Åsberg Depression Rating Scale (MADRS) total scoreTime frame: Change from Baseline to Week 6

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Axsome Research Site

    New York, New York

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.